|
|
|
| Trends in age-, period- and cohort-specific incidence of hepatitis C in Chifeng City from 2008 to 2022 |
| LI Wenjun1,2, LI Hui2, YANG Jingyuan2, YANG Hong2, GAO Ya2, GAO Baicheng2, LI Yao2, ZHANG Qiyue2, QIU Yafei3
|
1. School of Public Health, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010110, China;
2. Inner Mongolia Autonomous Region Center for Disease Control and Prevention (Inner Mongolia Academy of Preventive Medicine), Hohhot, Inner Mongolia 010080, China;
3. Chifeng Center for Disease Control and Prevention, Chifeng, Inner Mongolia 024005, China |
|
|
|
|
Abstract Objective To explore incidence trend of hepatitis C in Chifeng City, Inner Mongolia Autonomous Region from 2008 to 2022, so as to provide the basis for formulating prevention and control measures for hepatitis C. Methods Data of reported hepatitis C cases in Chifeng City from 2008 to 2022 was collected through the Infectious Disease Information Reporting Management System. Trends in incidence of hepatitis C were analyzed using annual percent change (APC) and average annual percent change (AAPC). Impact of age, period and birth cohort on the risk of developing hepatitis C were analyzed by an age-period-cohort model. Results The annual average reported incidence rate of hepatitis C in Chifeng City was 59.13/105 from 2008 to 2022. The incidence showed an upward trend from 2008 to 2018 (APC=9.405%, P<0.05) and a downward trend from 2018 to 2022 (APC=-17.475%, P<0.05), but the overall trend was not statistically significant (AAPC=0.937%, P>0.05). The age-period-cohort model analysis showed that the incidence risks of hepatitis C in the residents aged 0 to 4 years and 45 to 84 years were higher than those in the residents aged 40 to 44 years (the control group). The incidence risk of hepatitis C increased with age from 40 to 79 years. Compared with 2008-2012, the incidence risk of hepatitis C showed an increasing trend followed by a decline in 2008-2022. The incidence risk was higher in 2013-2017 and lower in 2018-2022 than in 2008-2012. The incidence risk of hepatitis C showed an increasing trend followed by a decreasing trend by using the birth cohort from 1968 to 1972 as the control. The birth cohort from 1953 to 1977 had a higher incidence risk of hepatitis C than other birth cohorts. Conclusions The overall incidence of hepatitis C in Chifeng City from 2008 to 2022 appeared a tendency towards a decline, and the incidence risk increased with age. Screening and health education for the elderly and high-risk birth cohorts should be strengthened.
|
|
Received: 27 December 2023
Revised: 18 March 2024
Published: 20 June 2024
|
|
|
|
|
|
[1] Word Health Organization.Hepatitis C[EB/OL].[2024-03-18].https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
[2] CUI F Q,BLACH S,MANZENGO MINGIEDI C,et al.Global reporting of progress towards elimination of hepatitis B and hepatitis C[J].Lancet Gastroenterol,2023,8(4):332-342.
[3] The Lancet Gastroenterology Hepatology.The hunt for a vaccine for hepatitis C virus continues[J].Lancet Gastroenterol Hepatol,2021,6(4):1-2.
[4] 李慧,萨如拉,王波,等.2008—2020年内蒙古自治区丙型病毒性肝炎流行特征分析[J].现代预防医学,2022,49(7):1322-1326.
[5] 高毅敏.内蒙古赤峰市2009—2015年丙型肝炎流行特征分析[J].疾病监测与控制,2016,10(8):640,648-649.
[6] 刘德,陈培培,娄培安,等.1990—2019年江苏省乙型肝炎病毒感染相关肝癌发病和死亡趋势分析[J].中华疾病控制杂志,2023,27(10):1221-1227.
[7] 马莹莹,李丽娟.我国丙型病毒性肝炎分布综述[J].昆明学院学报,2020,42(6):98-101.
[8] 刘锐,蔺茂文,江鸿,等.2008—2022年荆州市丙型病毒性肝炎发病的年龄、时期、队列趋势分析[J].预防医学,2023,35(10):871-876.
[9] 中华人民共和国国家卫生健康委员会疾病预防控制局.关于印发消除丙型肝炎公共卫生危害行动工作方案(2021—2030年)的通知[EB/OL].[2024-03-18].http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml.
[10] 李雨婷,范永君,韩常新.辽宁省大连市新型冠状病毒肺炎疫情后其他传染病流行特征变化分析[J].预防医学论坛,2023,29(1):54-57.
[11] 高禄化,聂青和.HCV母婴传播的分子机制及危险因素[J].临床肝胆病杂志,2017,33(6):1082-1087.
[12] 王辛未,孙群露,饶展宏,等.2005—2016年深圳市宝安区丙型肝炎报告发病率的年龄-时期-队列分析[J].中国艾滋病性病,2018,24(3):268-271.
[13] ODENWALD M A,PAUL S.Viral hepatitis:past,present,and future[J].World J Gastroenterol,2022,28(14):1405-1429.
[14] 付鸿臣,徐杰.我国50岁及以上新报告男性HIV感染者感染方式相关研究进展[J].中国艾滋病性病,2023,29(8):935-938.
[15] 樊苏红,王新华,张义,等.2005—2021年渭南市丙型肝炎流行特征分析[J].医学动物防制,2024,40(2):156-160.
[16] 魏霞,杨莉.我国丙型病毒性肝炎治疗药物医疗保障政策[J].临床药物治疗杂志,2021,19(12):1-5.
[17] 陈楚莹,陈秀云,王曼,等.2006—2019年中山市丙型病毒性肝炎报告发病率的年龄-时期-队列分析[J].中华疾病控制杂志,2021,25(7):775-778.
[18] 李晓春,阎瑞雪,海燕,等.安钠咖滥用人群HCV感染影响因素分析[J].中国公共卫生,2016,32(11):1524-1527.
[19] GAO X F,CUI Q,SHI X,et al.Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland:a systematic review and meta-analysis[J/OL].BMC Infect Dis,2011,11[2024-03-18].https://doi.org/10.1186/1471-2334-11-88.
[20] 赵宇腾,蔡衍珊,许美振,等.广州市丙型肝炎感染影响因素分析[J].预防医学,2019,31(2):162-164,169. |
|
|
|
